BTK inhibition has showed its potency in clinics as well as in clinical trials for Small Lymphocytic Lymphoma [27], Chronic Lymphocytic Leukemia [27], Diffuse large B-cell Lymphoma [28], and Mantle Cell Lymphoma [29]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.